[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=8733292b5e37a4718122d3f5a48640c5899d7fdb56736210ef9ab28012393bcd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746722280,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 134343222,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=8733292b5e37a4718122d3f5a48640c5899d7fdb56736210ef9ab28012393bcd"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Healthcare Fund Q1 2025 Commentary",
    "summary": "The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=1a3e772994eccdb6909ebaf690d19c5d6dc90778298d31e6e0056c9c40e64062",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746715560,
      "headline": "Hartford Healthcare Fund Q1 2025 Commentary",
      "id": 134328189,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406458240/image_1406458240.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=1a3e772994eccdb6909ebaf690d19c5d6dc90778298d31e6e0056c9c40e64062"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)",
    "summary": "CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more on why CRSP is a Sell.",
    "url": "https://finnhub.io/api/news?id=9d7a0754dd7c3753f80fa4741e0a65a77d5211ae3772129ed86c6b2c857b7c1b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746693404,
      "headline": "CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)",
      "id": 134323048,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158320032/image_2158320032.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more on why CRSP is a Sell.",
      "url": "https://finnhub.io/api/news?id=9d7a0754dd7c3753f80fa4741e0a65a77d5211ae3772129ed86c6b2c857b7c1b"
    }
  }
]